Literature DB >> 18288941

Deregulation of the Akt pathway in human cancer.

Eriko Tokunaga1, Eiji Oki, Akinori Egashira, Noriaki Sadanaga, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara.   

Abstract

Akt (protein kinase B) is a serine/threonine kinase which is a central regulator of widely divergent cellular processes including proliferation, differentiation, migration, survival and metabolism. Akt is activated by a variety of stimuli, through growth factor receptors, in phosphatidylinositol 3-kinase (PI3K)-dependent manner. Akt is also negatively regulated by the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN). A disruption of normal Akt/PKB/PTEN signaling frequently occurs in many human cancers, which plays an important role in cancer development, progression and therapeutic resistance. Numerous studies have revealed the blockage of Akt signaling to result in apoptosis and growth inhibition of tumor cells. Therefore, this signaling pathway, including both upstream and downstream of Akt, has recently attracted considerable attention as a new target for effective cancer therapeutic strategies. In fact, many inhibitors of Akt pathway have been identified and clinical studies of some agents are ongoing. In this review, we describe Akt signaling pathway components and its cellular functions as well as the alterations in human cancers and the therapeutic approaches for targeting the Akt pathway in cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288941     DOI: 10.2174/156800908783497140

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  87 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome.

Authors:  A Villavicencio; A Goyeneche; C Telleria; K Bacallao; F Gabler; A Fuentes; M Vega
Journal:  Gynecol Oncol       Date:  2009-07-23       Impact factor: 5.482

3.  3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase.

Authors:  Véronique Calleja; Michel Laguerre; Banafshé Larijani
Journal:  J Chem Biol       Date:  2009-02-20

4.  Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.

Authors:  Francesca Buontempo; Tulin Ersahin; Silvia Missiroli; Serif Senturk; Daniela Etro; Mehmet Ozturk; Silvano Capitani; Rengul Cetin-Atalay; Maria Luca Neri
Journal:  Invest New Drugs       Date:  2010-07-14       Impact factor: 3.850

5.  Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.

Authors:  Markus P Ghadimi; Gonzalo Lopez; Keila E Torres; Roman Belousov; Eric D Young; Jeffery Liu; Kari J Brewer; Aviad Hoffman; Kristelle Lusby; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

6.  Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation.

Authors:  Y Liao; Y Wei; X Zhou; J-Y Yang; C Dai; Y-J Chen; N K Agarwal; D Sarbassov; D Shi; D Yu; M-C Hung
Journal:  Oncogene       Date:  2009-05-18       Impact factor: 9.867

7.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Authors:  Chad J Creighton; Xiaoyong Fu; Bryan T Hennessy; Angelo J Casa; Yiqun Zhang; Ana Maria Gonzalez-Angulo; Ana Lluch; Joe W Gray; Powell H Brown; Susan G Hilsenbeck; C Kent Osborne; Gordon B Mills; Adrian V Lee; Rachel Schiff
Journal:  Breast Cancer Res       Date:  2010-06-22       Impact factor: 6.466

8.  Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway.

Authors:  Guo-Qing Li; Juan Xie; Xiao-Yong Lei; Li Zhang
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

9.  A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice.

Authors:  Boris Shor; Druie Cavender; Crafford Harris
Journal:  BMC Immunol       Date:  2009-05-20       Impact factor: 3.615

10.  Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.

Authors:  Jin-E Yao; Min Yan; Zhong Guan; Chao-Bin Pan; Liang-Ping Xia; Chuan-Xing Li; Li-Hui Wang; Zi-Jie Long; Yan Zhao; Ming-Wei Li; Fei-Meng Zheng; Jie Xu; Dong-Jun Lin; Quentin Liu
Journal:  Mol Cancer       Date:  2009-11-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.